drugset / Trial / NCT00919451

Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy

NCT00919451

NaSingle-groupOpen-labelTreatment

Summary

Study 1B: Ciclosporin in the management of steroid resistant Type 1 Reactions in Leprosy Objective: A pilot study assessing the efficacy and safety of Ciclosporin as a second -line drug in patients with Type 1 Reactions who have not responded to a 12 week course of Prednisolone.

Timeline

Start
2010-08
Primary completion
2013-06
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 7.5 mg/kg

Indications